Search results for "Colorectal Neoplasms."

showing 10 items of 431 documents

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.

2013

J. Balmana1, F. Balaguer2, A. Cervantes3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Department of Medical Oncology, Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona; Department of Gastroenterology, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain; Department of Medical Oncology, Tumor Biology Clinic, Albert Ludwigs University, Freiburg, Germany;

Riskmedicine.medical_specialtyColorectal cancerChemopreventionDNA Mismatch RepairDNA GlycosylasesNeoplastic Syndromes Hereditaryhealth services administrationMedicineHumansGenetic Predisposition to DiseaseGenetic TestingMultiple PolypsSigmoidoscopyEarly Detection of CancerAgedTumor biologybusiness.industryBrain NeoplasmsGeneral surgeryHematologyColonoscopyFamilial riskMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposishumanitiesClinical PracticeEuropeOncologyAdenomatous Polyposis Colipopulation characteristicsFemaleMicrosatellite InstabilitybusinessColorectal NeoplasmsColorectal Surgerygeographic locationsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Direct Identification of Each Specific Mutation in Codon 12 and 13 of ci-ki-ras2 by SSCP Analysis

1998

We compared the SSCP behaviour of the DNA fragments containing c-ki-ras 2 wild type 12 and 13 codons or each of the 12 possible point mutated sequences in these two codons. We found that a single electrophoresis condition was sufficient to distinguish each specific mutation from the other 11 and from the wild type sequence. This observation makes it possible to identify each specific mutation directly by SSCP without any need for reamplification and sequencing.

SSCP analysisBiophysicsBiologyBiochemistryFrameshift mutationProto-Oncogene Proteins p21(ras)chemistry.chemical_compoundGene FrequencyHumansCloning MolecularRas2CodonMolecular BiologyPolymorphism Single-Stranded ConformationalSequence (medicine)GeneticsSpecific mutationCarcinomaWild typeSingle-strand conformation polymorphismDNA NeoplasmCell BiologyMolecular biologyGenes raschemistryMutationElectrophoresis Polyacrylamide GelColorectal NeoplasmsDNABiochemical and Biophysical Research Communications
researchProduct

HSP110 promotes colorectal cancer growth through STAT3 activation.

2017

IF 7.932; International audience; Heat shock protein 110 (HSP110) is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps cells survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently shown that colorectal cancer patients with microsatellite instability (MSI) had an improved response to chemotherapy because they harbor an HSP110-inactivating mutation (HSP110DE9). In this work, we used patient biopsies, human colorectal cancer cells grown in vitro and in vivo (xenografts), and intestinal crypts to demonstrate that HSP110 is also involved in colon cancer growth. We showed that HSP110 induces colon cancer ce…

STAT3 Transcription Factor0301 basic medicineCancer ResearchColorectal cancerBiopsyMice Nudecolorectal cancer[SDV.CAN]Life Sciences [q-bio]/CancerMouse model of colorectal and intestinal cancerBiologymedicine.disease_causeMolecular oncology[ SDV.CAN ] Life Sciences [q-bio]/CancerSTAT3Mice03 medical and health sciences0302 clinical medicineGrowth factor receptorCell Line TumorGeneticsmedicineAnimalsHumansHSP110 Heat-Shock ProteinsIntestinal MucosaPhosphorylationSTAT3Molecular BiologyCell ProliferationMicrosatellite instabilityCell cyclemedicine.diseaseMolecular biologydigestive system diseases3. Good health030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinFemaleColorectal NeoplasmsCarcinogenesisNeoplasm TransplantationHSP110Protein Binding
researchProduct

FACS-based protocol to assess cytotoxicity and clonogenic potential of colorectal cancer stem cells using a Wnt/β-catenin signaling pathway reporter

2021

Summary Cancer stem cells (CSCs) play a key role in tumor initiation and progression. A real-time tool to evaluate the activation of CSC-specific signaling pathways is crucial for the study of this cancer cell subset. Here, we present a protocol to monitor, in vitro, the activation of Wnt/β-catenin signaling pathway, which is considered a functional biomarker for colorectal CSCs (CR-CSCs). This flow-cytometry-based protocol allows it to isolate CR-CSCs and to evaluate their cytotoxicity upon anti-tumor treatments. For complete details on the use and execution of this protocol, please refer to Di Franco et al. (2021).

Science (General)Colorectal cancerTumor initiationBiologyGeneral Biochemistry Genetics and Molecular BiologyQ1-390Cancer stem cellmedicineProtocolHumansFlow Cytometry/Mass CytometryClonogenic assayWnt Signaling PathwayCancerGeneral Immunology and MicrobiologyGeneral NeuroscienceStem CellsWnt signaling pathwayCancerCell Biologymedicine.diseaseFlow CytometryMolecular/Chemical ProbesCancer cellcolorectal cancers cancer stem cells FACS Wnt.Cell isolationCancer researchNeoplastic Stem CellsCell-based AssaysStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioColorectal NeoplasmsSignal TransductionSTAR Protocols
researchProduct

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

2022

Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-…

Settore MED/06 - Oncologia MedicaHematologyMMR deficiencyColorectal cancerMMRPD-1/PD-L1DNA Mismatch RepairTumor-agnostic therapyOncologyNeoplasmsSolid tumorsHumansMicrosatellite InstabilityImmunotherapyColorectal NeoplasmsMSI
researchProduct

Colorectal cancer: An update on the effects of lycopene on tumor progression and cell proliferation

2017

Colorectal cancer (CRC) is one of the most common cancers worldwide. Various factors, including oxidative stress, where excessive productions of reactive oxygen species (ROS) and reactive nitrogen species (RNS) occur, contribute to its pathogenesis. Numerous studies have investigated the effect of antioxidant substances derived from food such as fruits and vegetables; however, data on Lycopene are still rare. Studies on HT-29 colorectal cancer cells and on animal models have shown that lycopene has effects on cell proliferation and on the progression of the CRC by interacting with various cellular signaling pathways. This analysis of the literature focused on the antioxidant effect of lycop…

Settore MED/06 - Oncologia MedicaSettore BIO/11 - Biologia MolecolareNeoplasms ExperimentalCarotenoidsSettore MED/18 - Chirurgia GeneraleLycopeneAnimalsHumanscolorectal cancer antioxidant effects cell proliferationColorectal NeoplasmsReactive Oxygen SpeciesCell ProliferationSignal Transduction
researchProduct

Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.

1996

gammadelta T cells can be grouped into discrete subsets based upon their expression of T cell receptor (TCR) variable (V) region families, their tissue distribution, and their specificity. Vdelta2+ T cells constitute the majority of gammadelta T cells in peripheral blood whereas Vdelta1+T cells reside preferentially in skin epithelium and in the intestine. gammadelta T cells are envisioned as first line host defense mechanisms capable of providing a source of immune effector T cells and immunomodulating cytokines such as interleukin (IL) 4 or interferon (IFN) gamma. We describe here the fine specificity of three distinct gammadelta+ tumor-infiltrating lymphocytes (TIL) obtained from patient…

T cellMolecular Sequence DataImmunologySequence Homologychemical and pharmacologic phenomenaBiologyCell LineInterferon-gammaMiceInterleukin 21Lymphocytes Tumor-InfiltratingAntigens NeoplasmT-Lymphocyte SubsetsCulture TechniquesmedicineAnimalsHumansImmunology and AllergyCytotoxic T cellAmino Acid SequenceNeoplasms Glandular and EpithelialRNA MessengerIL-2 receptorAntigen-presenting cellLymphokine-activated killer cellBase SequenceInterleukin-7Receptors Antigen T-Cell gamma-deltaArticlesNatural killer T cellKidney NeoplasmsPancreatic Neoplasmsmedicine.anatomical_structureImmunologyCancer researchColorectal NeoplasmsCell Adhesion MoleculesCD8Interleukin-1Journal of Experimental Medicine
researchProduct

Antisense gene therapy using anti-k-ras and antitelomerase oligonucleotides in colorectal cancer

2005

Aim: to test the efficacy of anti-k-ras and antitelomerase oligonucleotides for disabling colorectal cancer cell growth. Material and methods: an established human colorectal cancer cell line (SW 480, ATTC ® ) was used. Oligodeoxiribonucleotides (ODNs) have a phosphorotioate modification to ensure intracellular intake. We used an antitelomerase ODN (Telp5) and two anti-k-ras ODNs (AS-KRAS and ISIS). AS-KRAS is designed to join the k-ras oncogene’s exon 1. ISIS links to the terminal transcription unit 5’ of k-ras. Telp5 joins the template region of the hTR telomerase subunit. ODNs have been tested in different concentrations (1, 5, 10, 20 micromolar). Cell viability has been tested at 48 and…

TelomeraseColorectal cancerAntisense therapyK-ras oncogenemedicine.disease_causeOligodeoxyribonucleotides AntisenseCell Line TumormedicineHumansViability assayTelomeraseOligoribonucleotidesOncogeneOligonucleotideCell growthbusiness.industryGastroenterologyGenetic TherapyGeneral Medicinemedicine.diseaseColorectal cancerGenes rasImmunologyCancer researchKRASColorectal NeoplasmsbusinessSoftwareIntracellularRevista Española de Enfermedades Digestivas
researchProduct

High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells.

2009

AIM: To analyze the relevance of the microRNA miR-196a for colorectal oncogenesis. METHODS: The impact of miR-196a on the restriction targets HoxA7, HoxB8, HoxC8 and HoxD8 was analyzed by reverse transcription polymerase chain reaction (RT-PCR) after transient transfection of SW480 cancer cells. The miR-196a transcription profile in colorectal cancer samples, mucosa samples and diverse cancer cell lines was quantified by RT-PCR. Transiently miR-196a-transfected colorectal cancer cells were used for diverse functional assays in vitro and for a xenograft lung metastasis model in vivo. RESULTS: HoxA7, HoxB8, HoxC8 and HoxD8 were restricted by miR-196a in a dose-dependent and gene-specific mann…

Transcription GeneticColorectal cancerColonTransplantation HeterologousMouse model of colorectal and intestinal cancerBiologymedicine.disease_causeMiceCell Line TumormicroRNAmedicineCell AdhesionAnimalsHumansProtein kinase BCell ProliferationAkt/PKB signaling pathwayGastroenterologyGeneral MedicineOriginal Articlesmedicine.diseaseReverse transcription polymerase chain reactionMicroRNAsPhenotypeCancer cellCancer researchCarcinogenesisColorectal NeoplasmsNeoplasm TransplantationSignal TransductionWorld journal of gastroenterology
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2019

Patient‐derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

Tumor Markers and SignaturesCMSShort Reportcolorectal cancerXenograft Model Antitumor AssaysDisease Models AnimalMicecell proliferationxenograft CMStumor subtypeAnimalsHeterograftsHumansxenograftColorectal NeoplasmsPDX
researchProduct